Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in such patients.
Praeguseks ajaks pole Rebif’ i kasutamist primaarse progresseerumisega sclerosis multiplex' iga patsientidel uuritud ning seega ei tohiks nendel patsientidel ravimit kasutada.